How can microRNAs be used as potential biomarkers and therapeutic targets in the management of ovarian cancer?
['           in the carcinogenesis of ovarian cancer through deregulation of cell proliferation.             They may be novel biomarkers for early detection or therapeutic targets of ovarian             cancer", "MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management", " The study suggests that the beneficial impact of the addition of paclitaxel on EOC survival was significantly linked to let-7a levels, and that miRNAs such as let-7a may be a useful marker for selection of chemotherapeutic agents in EOC management", "miR-200c has potential as a predictor of survival, and is a biomarker of relapse, in stage I EOC", "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer", " our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer", "miRNAs-21, 92 and 93 are known oncogenes with therapeutic and biomarker potential", "Serum miR-132, miR-26a, let-7b, and miR-145 could be considered as potential candidates as novel biomarkers in serous ovarian cancer"]']
MicroRNAs can serve as potential biomarkers for early detection or therapeutic targets in the management of ovarian cancer. For example, miRNAs like let-7a, let-7i, miR-200c, miR-21, miR-92, miR-93, miR-132, miR-26a, let-7b, and miR-145 have been identified as biomarkers with therapeutic and predictive potential in ovarian cancer management. They can help in selecting chemotherapeutic agents, predicting survival, modulating chemotherapy response, and identifying relapse in patients with ovarian cancer.
[]